Lurbinectedin for neuroendocrine tumors

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Aug 2025: Trial registered, NCT07121478
  2. 23 Sep 2025: Trial started, NCT07121478

The trials

NCT07121478: Patients With High-grade Pancreatic Neuroendocrine Tumors

State
Under way
Phase
Phase 2
People
46 planned
Started
23 Sep 2025
Primary completion
1 Mar 2027
Arms
single arm
Results
None posted
  1. 13 Aug 2025: Trial registered
  2. 23 Sep 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Lurbinectedin 4 MG Injection [Zepzelca], Zepsyre, Zepzelca.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.